Avanir's Nuedexta off to a slow start; Hikma 's lower targets based on political unrest;

@FiercePharma: Sanofi eyes cost cuts and deals for vet unit. News | Follow @FiercePharma

> Avanir Pharmaceuticals' Nuedexta is off to a slow start after being approved to treat patients with pseudobulbar affect, a condition in which patients with underlying neurological diseases have trouble controlling their emotions. Story

> Hikma Pharmaceuticals stuck to its guidance of seven percent revenue growth in 2011, around half 2010's level, as it manages the impact of political turmoil in its North Africa and Middle East markets. Report

> Danish biopharma firm Genmab reported a narrower loss for the first quarter than a year ago and kept its outlook for the full year 2011 steady. Article

> Inspire Pharmaceuticals, which is the target of a Merck acquisition bid, said its first-quarter loss widened, partly because of a $12.2 million restructuring charge. Story

> Use of the intravenous skin whitener glutathione (Glutathione IV) may be gaining popularity, but it may also be inviting potentially serious harm, health officials said. Item

> Lonza is to invest 24 million Swiss francs to expand its cytotoxic manufacturing capabilities in Visp, Switzerland, in response to demand for cytotoxic APIs used in oncology therapeutics. News

Biotech News

 @FierceBiotech: PBM chief says soaring biotech sector will inspire M&A blitz. Article | Follow @FierceBiotech

 @JohnCFierce: Halozyme gets $9M upfront, $74M in milestones from ViroPharma for Cinryze (subcutaneous) pact. Report | Follow @JohnCFierce

> Pharma CEOs talk tough about unproductive R&D spending. Item 

> Shire in the hunt for promising new stem cell tech. Story 

> GSK, AZ join hands to create new center for collaborative drug research. Report 

> Medco chief keeping close tabs on 40-plus biosimilars in development. Item 

> GSK venture group backs SpringLeaf in $15M round. News 

Vaccines News

> Inovio's cervical dysplasia vax shows Ph1 promise. Report 

> Prevnar-13 effective in adults over 50 in Ph3 trial. Item 

> GAVI Alliance pours $100M into meningitis vaccine. Story 

> FDA okays Sanofi's microinjection flu vaccine. News‎

> Gates leads $23.4M in funding for HIV/AIDS vaccine. Item 

Manufacturing News

> Pet generics: The next frontier. Item 

> Update: Drug shortages business opportunity gains steam. Story 

> Expert provides insight into global labeling challenges. Item

> New GSK CFO eyeing manufacturing, R&D. Report 

> Big 3 distributors hold big pharma survival clues. Article 

> API mischief may underlie drug shortages. News

And Finally... Scientists have used a genetically re-engineered herpes virus that hunts down and infects cancerous tumors and then prompts cancers to secrete a biomarker and reveal their presence. Report

Suggested Articles

Novartis is rolling out positive interim phase 3 data on Zolgensma in Europe, which could support the recent launch of the SMA gene therapy there.

The new cost-cutting goal comes on top of a €2.6 billion annual savings target the company already laid out in a revamp initiated in 2018.

As hearings continued on Capitol Hill, a congressional committee said Novartis, Amgen and Mallinckrodt used routine price hikes to meet sales targets.